J. Kolitz

J. Kolitz, K. Jhaveri, R. Wanchoo, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

H. Kantarjian, J. Cortes, J. Kolitz, 2015, Cancer.

CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis

J. Kolitz, Xinmin Zhang, C. Ghiuzeli, 2022, Leukemia research reports.

Treatment of Aggressive Non‐Hodgkin's Lymphoma in Elderly Patients With Thiotepa, Novantrone (Mitoxantrone), Vincristine, Prednisone (TNOP)

J. Kolitz, D. Budman, V. Vinciguerra, 2001, American journal of clinical oncology.

and whites with acute myeloid leukemia Differences in prognostic factors and outcomes in African Americans

Edward J. Lee, C. Bloomfield, R. Larson, 2011 .

Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia.

J. Byrd, R. Garzon, A. de la Chapelle, 2020, Cancer discovery.

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Haematologica.

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia

C. Bloomfield, J. Byrd, S. Liyanarachchi, 2019, Clinical Cancer Research.

Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia

C. Bloomfield, J. Byrd, K. Mrózek, 2016, British journal of haematology.

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA

C. Bloomfield, J. Byrd, S. Liyanarachchi, 2018, Leukemia.

Cytokines with possible clinical utility.

F. Herrmann, R. Mertelsmann, J. Kolitz, 1987, Haematology and blood transfusion.

Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.

J. Byrd, R. Larson, F. Appelbaum, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

M. Caligiuri, C. Bloomfield, K. Metzeler, 2012 .

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701

Scott E. Smith, R. Larson, M. Liedtke, 2018, Blood.

FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2007 .

The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011)

R. Larson, F. Appelbaum, A. Belch, 2013, Leukemia & lymphoma.

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

J. Dipersio, H. Kantarjian, J. Cortes, 2012, Cancer.

Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin.

J. Kolitz, K. Welte, G. Miller, 1988, Cancer research.

Primary Low-Grade B-Cell Lymphoma of Skull With Translocation Between Immunoglobulin and Interferon Regulatory Factor 4 Genes

J. Kolitz, S. Spitzer, M. Nasim, 2020, International journal of surgical pathology.

Human interleukin 2 gene is located on chromosome 4.

K. Grzeschik, R. Mertelsmann, J. Kolitz, 1984, Cancer investigation.

Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.

J. Cortes, J. Kolitz, R. Stone, 2016 .

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma

V. Diehl, F. Herrmann, J. Kolitz, 2004, Cancer Immunology, Immunotherapy.

The immunotherapy of human cancer with interleukin 2: present status and future directions.

R. Mertelsmann, J. Kolitz, 1991, Cancer investigation.

Characterization of structurally deﬁned epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells

Wentian Li, N. Chiorazzi, S. Stilgenbauer, 2009 .

Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia.

P. Gregersen, N. Chiorazzi, J. Kolitz, 1997, Journal of immunology.

Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.

S. Soignet, D. Scheinberg, J. Kolitz, 2000, Blood.

A study of lymphoma of large granular lymphocytes with modern modalities: Report of two cases and review of the literature

P. Koduru, M. Susin, J. Kolitz, 1992, American journal of hematology.

Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.

J. Fried, J. Kolitz, B. Clarkson, 1988, Acta haematologica.

Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance

A. Rosenwald, N. Chiorazzi, K. Rai, 2012, Haematologica.

Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis

J. Kolitz, D. Budman, V. Vinciguerra, 2001, Cancer Chemotherapy and Pharmacology.

Activated CLL cells regulate IL17F producing Th17 cells in miR155 dependent and outcome specific manners.

N. Chiorazzi, K. Rai, J. Kolitz, 2022, JCI insight.

Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL

K. Stamatopoulos, Xiao-Jie Yan, N. Chiorazzi, 2021, Leukemia.

A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.

C. Bloomfield, R. Vij, R. Larson, 2005 .

Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

C. Bloomfield, R. Larson, G. Lozanski, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.

R. Larson, W. Stock, J. Kolitz, 2004 .

Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503)

C. Bloomfield, R. Larson, K. Mrózek, 2016, Leukemia.

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

J. Byrd, R. Garzon, K. Mrózek, 2020, Blood.

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2014, Leukemia.

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

C. Bloomfield, M. Buyse, R. Larson, 2011, Blood.

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2007, Blood.

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

Morphological, ultrastructural, and genetic characterization of an unusual T‐cell lymphoma in a patient with sinus histiocytosis with massive lymphadenopathy

P. Koduru, M. Susin, J. Kolitz, 1995, American journal of hematology.

Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells.

P. Gregersen, N. Chiorazzi, M. Dono, 1996, The Journal of clinical investigation.

Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature.

J. Kolitz, C. Devoe, J. Laser, 2014, International journal of clinical and experimental pathology.

Intrathoracic Myeloid Sarcoma

J. Kolitz, Arunabh Talwar, R. Shah, 2005 .

Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion

Xiao-Jie Yan, N. Chiorazzi, K. Rai, 2018, The Journal of Immunology.

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.

J. Cortes, J. Kolitz, J. Lancet, 2021, Blood advances.

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

N. Chiorazzi, K. Rai, M. Ferrarini, 1999, Blood.

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

Emanuela M. Ghia, Wentian Li, J. Byrd, 2022, Frontiers in Oncology.

Torque Teno Virus 10 Isolated by Genome Amplification Techniques from a Patient with Concomitant Chronic Lymphocytic Leukemia and Polycythemia Vera

Xiao-Jie Yan, N. Chiorazzi, K. Rai, 2011, Molecular medicine.

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.

J. Cortes, J. Kolitz, J. Lancet, 2021, The Lancet. Haematology.

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

Gregory L. Wheeler, E. Mardis, J. Byrd, 2022, Blood advances.

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically

C. Bloomfield, J. Byrd, K. Mrózek, 2019, Leukemia.

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome

C. Bloomfield, J. Byrd, A. de la Chapelle, 2018, Leukemia.

Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2005 .

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia

Karl W. Kroll, C. Bloomfield, J. Byrd, 2017, Leukemia.

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

Karl W. Kroll, C. Bloomfield, J. Byrd, 2017, Leukemia.

SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

J. Radich, R. Larson, F. Appelbaum, 2016 .

Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.

J. Gabrilove, M. Andreeff, J. Kolitz, 1989, Seminars in oncology.

Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.

C. Bloomfield, R. Larson, Daohai Yu, 2005 .

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

Pearlly Yan, Ralf Bundschuh, David Frankhouser, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A complex variant Philadelphia (Ph1) chromosome translocation involving chromosomes No. 11, 14, and 22 in a case of chronic myelogenous leukemia.

J. Kolitz, D. Budman, V. Vinciguerra, 1981, Cancer genetics and cytogenetics.

Very late relapse of acute myeloid leukemia

J. Kolitz, 2007, Leukemia & lymphoma.

Acquired factor VIII inhibitors—successful treatment with an oral outpatient regimen

J. Loscalzo, J. Kolitz, D. Budman, 1999, American journal of hematology.

Leukemia Group B study myeloid leukemia and MLL partial tandem duplication: a Cancer and Long-term disease-free survivors with cytogenetically normal acute

M. Caligiuri, P. Paschka, R. Larson, 2013 .

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Robert K. Stuart, Antje Hoering, Arthur C. Louie, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).

C. Bloomfield, C. Schiffer, R. Larson, 2001, Blood.

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

C. Bloomfield, R. Larson, S. George, 2005, Blood.

Acute Myeloid Leukemia and the Myelodysplastic Syndromes

J. Kolitz, 2006 .

Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)

K. Owzar, M. Ratain, R. Vij, 2014, Cancer Chemotherapy and Pharmacology.

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.

C. Bloomfield, R. Larson, J. Kurtzberg, 2005, Blood.

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.

M. Caligiuri, C. Bloomfield, R. Larson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

M. Caligiuri, C. Bloomfield, R. Larson, 2002, Blood.

Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.

Guido Marcucci, M. Caligiuri, C. Bloomfield, 2006, Blood.

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, R. Larson, 2001, Cancer research.

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

B. Cheson, R. Larson, F. Appelbaum, 2000, The New England journal of medicine.

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

R M Stone, S L George, M. Caligiuri, 2011, Leukemia.

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

Janice Gabrilove, Glenn Heller, J. Gabrilove, 1991 .

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808

M. Caligiuri, C. Bloomfield, R. Vij, 2013, Cancer.

TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells

T. Stankovic, N. Chiorazzi, K. Rai, 2015, The Journal of Immunology.

Binding of CLL Subset 4 B Cell Receptor Immunoglobulins to Viable Human Memory B Lymphocytes Requires a Distinctive IGKV Somatic Mutation

K. Stamatopoulos, Xiao-Jie Yan, N. Chiorazzi, 2017, Molecular medicine.

Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia

Steven L. Allen, Fabio Ghiotto, R. Foà, 2004, The Journal of experimental medicine.

Anna Tramontano, Fabio Ghiotto, M. Nardini, 2004, The Journal of clinical investigation.

In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia.

N. Chiorazzi, K. Rai, J. Kolitz, 2009, Blood.

BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia

M. Caligiuri, C. Bloomfield, C. Plass, 2001, Proceedings of the National Academy of Sciences of the United States of America.

of chromosome 11 loci Novel methylation targets in de novo acute myeloid leukemia with prevalence

M. Caligiuri, C. Bloomfield, F. Wright, 2010 .

Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci.

M. Caligiuri, C. Bloomfield, F. Wright, 2001, Blood.

IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.

Xiao-Jie Yan, N. Chiorazzi, K. Rai, 2012, Blood.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

Christian Langer, Guido Marcucci, M. Caligiuri, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.

C. Bloomfield, M. Ross, M. Radmacher, 2008, Blood.

Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process.

Xiao-Jie Yan, N. Chiorazzi, K. Rai, 2016, JCI insight.

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

J. Byrd, R. Larson, F. Appelbaum, 2005, Blood.

Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations.

P. Gregersen, F. Batliwalla, N. Chiorazzi, 2004, Blood.

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes.

Xiao-Jie Yan, N. Chiorazzi, K. Rai, 2002, Blood.

Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target

O. Abdel-Wahab, Xiao-Jie Yan, N. Chiorazzi, 2021, Leukemia.

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Annette Lee, P. Gregersen, Xiao-Jie Yan, 2011, Blood.

Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.

N. Chiorazzi, K. Rai, J. Kolitz, 2010, Blood.

Multi-Parameter Phenotypic Analysis of Members of Chronic Lymphocytic Leukemia Clones Identifies Distinct Proliferative and Resting/Re-Entry Compartments with Discrete Gene Expression Profiles.

Wentian Li, Xiao-Jie Yan, N. Chiorazzi, 2009 .

Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells.

Wentian Li, N. Chiorazzi, S. Stilgenbauer, 2009, Blood.

Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course

N. Chiorazzi, S. Bruno, S. Kasar, 2021, Frontiers in Oncology.

G. Gaidano, N. Chiorazzi, K. Rai, 2006, Molecular medicine.

From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only.

Xiao-Jie Yan, N. Chiorazzi, K. Rai, 2007 .

Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.

M. Caligiuri, C. Bloomfield, R. Larson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.

J. Kolitz, D. Budman, V. Vinciguerra, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia

Guido Marcucci, Stefano Volinia, Andrew J. Carroll, 2014, Proceedings of the National Academy of Sciences.

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.

Guido Marcucci, Stefano Volinia, Jessica Kohlschmidt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

J. Byrd, R. Garzon, K. Mrózek, 2021, Blood advances.

Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)

C. Bloomfield, J. Byrd, K. Mrózek, 2016, Haematologica.

Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia

A. Krasnitz, J. Kendall, M. Wigler, 2020, Nucleic acids research.

Current therapeutic strategies for acute myeloid leukaemia

J. Kolitz, 2006, British journal of haematology.

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

C. Bloomfield, R. Larson, K. Mrózek, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.

C. Bloomfield, R. Larson, K. Mrózek, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti‐B4‐blocked ricin or high‐dose cytarabine

C. Bloomfield, C. Reynolds, J. Sklar, 2003, Cancer.

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Importance of MN 1 Transcript Levels , and Biologic Insights From MN 1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas

J. Bertino, J. Crown, J. Kolitz, 1991, Investigational New Drugs.

mouse bladder gene regulation Neurokinin 1 receptors and neprilysin modulation of

Wentian Li, Xiao-Jie Yan, N. Chiorazzi, 2013 .

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.

J. Gabrilove, M. Andreeff, J. Kolitz, 1991, Blood.

Human Malignancies

J. Kolitz, N. Riedel, 1989, Springer Berlin Heidelberg.

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.

C. Bloomfield, J. Byrd, R. Garzon, 2021, Blood advances.

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.

C. Bloomfield, R. Larson, K. Mrózek, 2020, Blood advances.

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

C. Bloomfield, R. Kittles, P. Paschka, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary extranodal marginal zone lymphoma of the endometrium: report of four cases and review of literature.

J. Kolitz, J. Laser, Xinmin Zhang, 2015, International journal of clinical and experimental pathology.

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Blood.

Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2007 .

Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia

C. Bloomfield, J. Byrd, R. Garzon, 2019, Haematologica.

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).

C. Bloomfield, J. Byrd, R. Vij, 2021, Blood advances.

Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials

R. Larson, S. George, J. Kolitz, 2016, American journal of hematology.

Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.

Edward J. Lee, R. Dodge, J. Kolitz, 1997, Blood.

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Leukemia.

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2013, Blood.

Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia

D. Neuberg, J. Kolitz, K. Stevenson, 2016, Cancer.

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

J. Kolitz, J. Lancet, L. Mayer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years

C. Bloomfield, J. Byrd, A. de la Chapelle, 2020, Leukemia.

myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study cytogenetically normal patients younger than 60 years with acute markers, poor outcome, and a distinct gene-expression signature in High BAALC expression associates with other molecular prognostic

M. Ross, M. Radmacher, P. Paschka, 2013 .

Leukemia Group B Study 9511 improved outcomes in adult acute lymphoblastic leukemia: Cancer and Effective asparagine depletion with pegylated asparaginase results in

C. Bloomfield, R. Larson, J. Kurtzberg, 2013 .

Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.

J. Bennett, J. Kolitz, A. Lundberg, 2010, Leukemia research.

Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders.

D. Heitjan, R. Mertelsmann, J. Kolitz, 1988, Blood.

T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.

N. Chiorazzi, K. Rai, J. Kolitz, 2012, Blood.

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lois Shepherd, John D Hines, R. Larson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.

Edward J. Lee, C. Bloomfield, R. Larson, 2004, Blood.

Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

R. Larson, F. Appelbaum, K. Rai, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).

J. Cortes, J. Kolitz, J. Lancet, 2017 .

Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.

J. Cortes, J. Kolitz, J. Lancet, 2020 .

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2008, Blood.

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

M. Caligiuri, C. Bloomfield, A. de la Chapelle, 2003, Blood.

Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status.

N. Chiorazzi, K. Rai, J. Kolitz, 2016, Clinical immunology.

Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation

E. Meffre, N. Chiorazzi, K. Rai, 2008, Molecular medicine.

Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia.

Wentian Li, Xiao-Jie Yan, N. Chiorazzi, 2011, Blood.

Group B Study leukemia patients with normal cytogenetics: a Cancer and Leukemia BAALC expression predicts clinical outcome of de novo acute myeloid

M. Caligiuri, R. Larson, D. Baldus, 2013 .

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Guido Marcucci, Jessica Kohlschmidt, Heiko Becker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Guido Marcucci, Heiko Becker, Sebastian Schwind, 2010, Blood.

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Klaus H. Metzeler, Guido Marcucci, Stefano Volinia, 2013, Leukemia.

A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes

Wentian Li, Mike Tipping, B. McCarthy, 2015, Immunologic Research.

Cytoplasmic myosin exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability

N. Chiorazzi, K. Rai, J. Kolitz, 2015, Leukemia.

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.

C. Bloomfield, R. Larson, K. Mrózek, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8

M. Caligiuri, M. Radmacher, K. Metzeler, 2014, Leukemia.

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

C. Bloomfield, M. Radmacher, P. Paschka, 2009 .

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.

C. Bloomfield, J. Byrd, K. Metzeler, 2018, Blood advances.

Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A

C. Bloomfield, J. Byrd, A. de la Chapelle, 2020, Proceedings of the National Academy of Sciences.

Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

C. Bloomfield, R. Larson, K. Mrózek, 2002, International journal of oncology.

Lymphoma of large granular lymphocytes

M. Susin, J. Kolitz, J. Chan, 1993 .

A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma

J. Gabrilove, P. Chapman, R. Mertelsmann, 1988, Investigational New Drugs.

Pharmacokinetics of recombinant interleukin 2 in humans.

P W Mansell, E. Hersh, R. Mertelsmann, 1990, Cancer research.

Synergism Between Cyclophosphamide and Interleukin-2

F. Herrmann, J. Kolitz, A. Lindemann, 2018 .

rearrangement recognize nonmuscle myosin heavy chain IIA Chronic lymphocytic leukemia antibodies with a common stereotypic

Xiao-Jie Yan, N. Chiorazzi, K. Rai, 2013 .

High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

C. Bloomfield, P. Paschka, R. Larson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).

S. Jhanwar, M. Andreeff, R. Mertelsmann, 1991, Leukemia & lymphoma.

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies

C. Bloomfield, J. Byrd, A. de la Chapelle, 2018, Leukemia.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).

C. Bloomfield, L. Garraway, Judit Jané-Valbuena, 2018, Blood advances.

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

C. Bloomfield, J. Byrd, R. Garzon, 2020 .

Myelodysplastic syndromes spatial clusters in disease etiology and outcome

E. Taioli, J. Kolitz, M. Sekeres, 2016, Leukemia & lymphoma.

A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia.

S. Jhanwar, J. Kolitz, B. Clarkson, 1992, Seminars in oncology.

Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study

C. Bloomfield, P. Paschka, R. Larson, 2008 .

Clinical and morphological features of cases of trisomy 13 in acute non-lymphocytic leukemia.

K. Rai, P. Koduru, J. Kolitz, 1996, Leukemia.

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Steven L. Allen, Fabio Ghiotto, N. Chiorazzi, 1999, Blood.

Outcomes in Older Patients with Newly Diagnosed, High‐risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX‐351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin: AML‐275

J. Cortes, J. Kolitz, J. Lancet, 2018, Clinical Lymphoma Myeloma and Leukemia.

A precision medicine classification for treatment of acute myeloid leukemia in older patients

C. Bloomfield, J. Byrd, R. Levine, 2021, Journal of Hematology & Oncology.

Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.

C. Bloomfield, J. Byrd, R. Larson, 2004, Annals of hematology.

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance)

Scott E. Smith, R. Larson, M. Liedtke, 2016 .

Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A

S. Lowe, M. Spector, I. Iossifov, 2012, Leukemia.

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma.

B. Nathwani, A. Tulpule, J. Kolitz, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2011 .

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Leukemia.

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study

K. Mrózek, W. Stock, A. Carroll, 2023, Leukemia.

miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53

M. Caligiuri, C. Bloomfield, M. Radmacher, 2014 .

Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).

J. Kolitz, J. Lancet, L. Mayer, 2007 .

Efficacy and Safety of Hydroxychloroquine Sulphate In Chronic Lymphocytic Leukemia: Clinical Trial Experience In Untreated Patients

N. Chiorazzi, K. Rai, J. Kolitz, 2010 .

Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

C. Bloomfield, C. Croce, R. Garzon, 2018, Blood.

Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.

C. Bloomfield, J. Byrd, K. Metzeler, 2021, Haematologica.

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission

J. Cortes, J. Kolitz, G. Schiller, 2020 .

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.

J. Kolitz, L. Mayer, E. Feldman, 2012, Leukemia research.

Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.

J. Kolitz, K. Welte, V. J. Merluzzi, 1988, Journal of biological response modifiers.

Coexpression of Interleukin 2 and HTLY III Messenger RNA in Patients with Acquired Immune Deficiency Syndrome

R. Mertelsmann, J. Kolitz, N. Riedel, 1989 .

Correction to: Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells

Wentian Li, Xiao-Jie Yan, N. Chiorazzi, 2022, Molecular Medicine.

Somatic Hypermutation In Stereotyped Subset 4 BCRs/mAbs of CLL Patients, Expressing IGHV4-34 gene, Edit Anti-DNA Reactivity

K. Stamatopoulos, N. Chiorazzi, K. Rai, 2010 .

Interleukin 2: a review.

R. Mertelsmann, J. Kolitz, K. Welte, 1985, Arzneimittel-Forschung.

Acute leukemias in adults.

J. Kolitz, 2008, Disease-a-month : DM.

Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.

J. Kolitz, B. Clarkson, C. Bührer, 1988, Oncology.

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

C. Bloomfield, R. Larson, W. Stock, 2012 .

A 17-Gene Leukemia Stem Cell (LSC) Score in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Reveals a Distinct Mutational Landscape and Refines Current European Leukemianet (ELN) Genetic Risk Stratification

C. Bloomfield, J. Byrd, R. Garzon, 2018, Blood.

Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010 .

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia

C. Bloomfield, C. Croce, S. Volinia, 2017, Oncotarget.

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

K. Mrózek, S. Baker, W. Stock, 2023, Blood advances.

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)

C. Bloomfield, J. Byrd, S. Volinia, 2016, Leukemia.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

M. Caligiuri, C. Bloomfield, Yue-zhong Wu, 2013, Blood.

Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells.

Wentian Li, N. Chiorazzi, S. Stilgenbauer, 2009, Blood.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations.

P. Gregersen, F. Batliwalla, N. Chiorazzi, 2004, Blood.

TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells

T. Stankovic, N. Chiorazzi, K. Rai, 2015, The Journal of Immunology.

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

M. Caligiuri, C. Bloomfield, J. Byrd, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance

A. Rosenwald, N. Chiorazzi, K. Rai, 2012, Haematologica.

Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

Xiao-Jie Yan, N. Chiorazzi, K. Rai, 2008, Blood.

Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report.

M. Tallman, J. Kolitz, J. Lancet, 2009 .

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

J. Kolitz, J. Lancet, L. Mayer, 2008 .

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

J. Cortes, J. Kolitz, R. Stone, 2018, Blood.

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

C. Bloomfield, M. Buyse, R. Larson, 2011, Blood.

Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia

Xiao-Jie Yan, N. Chiorazzi, K. Rai, 2013 .

BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism

K. Rai, J. Kolitz, S. Haque, 2024, Lymphatics.

Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

N. Salomonis, A. Carroll, J. Kolitz, 2023, Leukemia.

Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations

C. Bloomfield, J. Byrd, J. Kolitz, 2020, Leukemia.